Suppr超能文献

脉搏波速度估计可改善 COVID-19 患者全因死亡率的风险分层。

Estimated pulse wave velocity improves risk stratification for all-cause mortality in patients with COVID-19.

机构信息

Department of Clinical Therapeutics, National and Kapodistrian University of Athens School of Medicine, Athens, Greece.

Biosciences Institute, International Centre for Life, Vascular Biology and Medicine Theme, Faculty of Medical Sciences, Newcastle University, Central Parkway, Newcastle upon Tyne, NE1 3BZ, UK.

出版信息

Sci Rep. 2021 Oct 12;11(1):20239. doi: 10.1038/s41598-021-99050-0.

Abstract

Accurate risk stratification in COVID-19 patients consists a major clinical need to guide therapeutic strategies. We sought to evaluate the prognostic role of estimated pulse wave velocity (ePWV), a marker of arterial stiffness which reflects overall arterial integrity and aging, in risk stratification of hospitalized patients with COVID-19. This retrospective, longitudinal cohort study, analyzed a total population of 1671 subjects consisting of 737 hospitalized COVID-19 patients consecutively recruited from two tertiary centers (Newcastle cohort: n = 471 and Pisa cohort: n = 266) and a non-COVID control cohort (n = 934). Arterial stiffness was calculated using validated formulae for ePWV. ePWV progressively increased across the control group, COVID-19 survivors and deceased patients (adjusted mean increase per group 1.89 m/s, P < 0.001). Using a machine learning approach, ePWV provided incremental prognostic value and improved reclassification for mortality over the core model including age, sex and comorbidities [AUC (core model + ePWV vs. core model) = 0.864 vs. 0.755]. ePWV provided similar prognostic value when pulse pressure or hs-Troponin were added to the core model or over its components including age and mean blood pressure (p < 0.05 for all). The optimal prognostic ePWV value was 13.0 m/s. ePWV conferred additive discrimination (AUC: 0.817 versus 0.779, P < 0.001) and reclassification value (NRI = 0.381, P < 0.001) over the 4C Mortality score, a validated score for predicting mortality in COVID-19 and the Charlson comorbidity index. We suggest that calculation of ePWV, a readily applicable estimation of arterial stiffness, may serve as an additional clinical tool to refine risk stratification of hospitalized patients with COVID-19 beyond established risk factors and scores.

摘要

在 COVID-19 患者中进行准确的风险分层是指导治疗策略的主要临床需求。我们旨在评估脉搏波速度(ePWV)的预后作用,ePWV 是动脉僵硬度的标志物,反映了整体动脉完整性和衰老程度,在 COVID-19 住院患者的风险分层中的作用。这项回顾性、纵向队列研究分析了总共 1671 名受试者的人群,其中包括从两个三级中心连续招募的 737 名 COVID-19 住院患者(纽卡斯尔队列:n=471 名;比萨队列:n=266 名)和非 COVID-19 对照组(n=934 名)。使用经过验证的 ePWV 公式计算动脉僵硬度。ePWV 在对照组、COVID-19 幸存者和死亡患者中逐渐增加(每组调整后的平均增加 1.89 m/s,P<0.001)。使用机器学习方法,ePWV 提供了比包括年龄、性别和合并症在内的核心模型更高的增量预后价值和更好的死亡率再分类(核心模型+ePWV 与核心模型的 AUC 分别为 0.864 和 0.755)。当将脉压或高敏肌钙蛋白添加到核心模型或其包含年龄和平均血压的组成部分中时,ePWV 提供了类似的预后价值(所有 p<0.05)。最佳预后 ePWV 值为 13.0 m/s。ePWV 在 4C 死亡率评分(一种预测 COVID-19 死亡率的验证评分)和 Charlson 合并症指数上提供了附加的区分度(AUC:0.817 与 0.779,P<0.001)和再分类价值(NRI=0.381,P<0.001)。我们建议,计算 ePWV,一种易于应用的动脉僵硬度估计方法,可能成为除既定危险因素和评分外,用于 COVID-19 住院患者风险分层的附加临床工具。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2944/8511157/762ac8770a63/41598_2021_99050_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验